Genetic neurodegenerative disease

Orphanet code 183500 corresponds to a broad grouping category for genetic neurodegenerative diseases rather than a single, specific disease entity. Genetic neurodegenerative diseases encompass a wide range of inherited conditions characterized by progressive loss of structure or function of neurons in the brain and/or spinal cord. These disorders affect the central and peripheral nervous systems and can lead to problems with movement (ataxias, dystonias, motor neuron diseases), cognitive decline (dementias), or both. Examples within this category include Huntington disease, hereditary ataxias, hereditary spastic paraplegias, neuronal ceroid lipofuscinoses, and many others. Because this Orphanet code represents a classification group rather than a discrete clinical entity, the inheritance patterns, ages of onset, specific symptoms, and prevalence vary enormously depending on the individual disease. Inheritance can be autosomal dominant, autosomal recessive, X-linked, or mitochondrial. Age of onset ranges from neonatal to late adult life. Common features across many genetic neurodegenerative diseases include progressive motor dysfunction, cognitive deterioration, speech and swallowing difficulties, and loss of independence over time. Treatment for most genetic neurodegenerative diseases remains largely supportive and symptomatic, including physical therapy, occupational therapy, speech therapy, and pharmacological management of specific symptoms such as spasticity, seizures, or psychiatric manifestations. However, emerging gene therapies, antisense oligonucleotides, and enzyme replacement therapies are being developed or have been approved for select conditions within this group. Genetic counseling is recommended for affected individuals and their families to understand recurrence risks and available testing options.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Genetic neurodegenerative disease